Home/Pipeline/TLC502

TLC502

Immune disorders

PreclinicalActive

Key Facts

Indication

Immune disorders

Phase

Preclinical

Status

Active

Company

Taiwan Liposome Company

About Taiwan Liposome Company

Taiwanese biotech leveraging next‑gen lipid delivery for pain, metabolic and cell‑therapy medicines.

View full company profile

Therapeutic Areas

Orthopedics Pain Management Metabolic Disorders Immune Disorders Infectious Diseases Regenerative Medicine